A new study from researchers at The Catholic University of Korea finds that cannabidiol (CBD) may provide a promising treatment for rosacea, particularly when combined with the commonly used antibiotic metronidazole (MET).
Using an animal model of rosacea, scientists found that both CBD and MET significantly reduced redness, skin thickening, and mast cell infiltration. The most notable results were seen when the two treatments were combined.
In the study, mechanistic testing showed that CBD’s anti-inflammatory effects stem from its ability to suppress the MAPK signaling pathway, including ERK, JNK, and p38 regulators. These pathways play a central role in triggering skin inflammation.
CBD also reduced the production of proinflammatory cytokines and chemokines, further supporting its role in immune modulation.
With roughly 5.5% of the global population affected by rosacea and current treatments often producing limited results or unwanted side effects, researchers say CBD may represent a novel and effective approach to managing the chronic skin condition.
More articles from The Marijuana Herald can be found below.
